Share ownership Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:41 08/07/2025 BST			5-day change	1st Jan Change
257.70 ^CHF	+0.23%		-0.27%	+0.86%

07:25am	ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	ZD
07-08	Deutsche Bank Remains Cautious on Pharmaceutical Sector Ahead of Earnings Season	FW

Share class: Roche Holding AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	106,691,000	29,021,344 ( 27.2 %)	0	87.84 %
Stock B	1	702,562,700	681,822,598 ( 97.05 %)	13,853,005 ( 1.972 %)

Major shareholders: Roche Holding AG

Name	Equities	%	Valuation
State Street Global Advisors Ltd. 0.2209 %	1,551,648	0.2209 %	504 M CHF
Sjunde AP-fonden 0.1471 %	1,033,467	0.1471 %	335 M CHF
Nordea Investment Management AB 0.1291 %	907,101	0.1291 %	294 M CHF
DWS CH AG 0.1089 %	765,088	0.1089 %	248 M CHF
Baloise Asset Management AG 0.1076 %	756,252	0.1076 %	245 M CHF
Amundi Asset Management SASU (Investment Management) 0.1021 %	717,446	0.1021 %	233 M CHF
Banque Cantonale de Genève (Investment Management) 0.0878 %	616,625	0.0878 %	200 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.0787 %	553,248	0.0787 %	180 M CHF
LLB Asset Management AG 0.0744 %	522,562	0.0744 %	170 M CHF
Capfi Delen Asset Management NV 0.0744 %	522,542	0.0744 %	170 M CHF
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Aristotle Capital Management LLC 0.0404 %	2,270,935	0.0404 %	93 M CHF
Saratoga Research & Investment Management 0.036 %	2,022,209	0.036 %	83 M CHF
Pacer Advisors, Inc. 0.021 %	1,178,534	0.021 %	48 M CHF
Boston Common Asset Management LLC 0.005795 %	325,732	0.005795 %	13 M CHF
Old National Bank (Investment Management) 0.004519 %	253,991	0.004519 %	10 M CHF
Altrius Capital Management, Inc. 0.00338 %	189,993	0.00338 %	8 M CHF
Meritage Portfolio Management, Inc. 0.002892 %	162,546	0.002892 %	7 M CHF
Bard Financial Services, Inc. 0.002471 %	138,900	0.002471 %	6 M CHF
Port Street Investments LLC 0.002319 %	130,352	0.002319 %	5 M CHF
AR Asset Management, Inc. 0.001922 %	108,000	0.001922 %	4 M CHF
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Hoffmann Family 64.97 %	69,318,000	64.97 %	23 948 M CHF
Maja Oeri 7.584 %	8,091,900	7.584 %	2 796 M CHF
Severin Schwan 0.2382 %	254,090	0.2382 %	88 M CHF
zCapital AG 0.0984 %	105,000	0.0984 %	36 M CHF
State Street Global Advisors Ltd. 0.0642 %	68,512	0.0642 %	24 M CHF
Sjunde AP-fonden 0.0451 %	48,151	0.0451 %	17 M CHF
Valiant Bank AG 0.0414 %	44,119	0.0414 %	15 M CHF
LLB Asset Management AG 0.0346 %	36,867	0.0346 %	13 M CHF
Chikara Investments LLP 0.0344 %	36,697	0.0344 %	13 M CHF
Swiss Rock Asset Management AG 0.0319 %	33,989	0.0319 %	12 M CHF
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	11.06%
Institutional	5.36%
Associated Banc-Corp	0.01%
Unknown	83.57%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	11.06%
Switzerland	1.3%
United States	1.23%
United Kingdom	0.58%
Sweden	0.3%
Germany	0.25%
France	0.22%
Ireland	0.2%
Spain	0.14%
Norway	0.13%
Luxembourg	0.13%
Italy	0.12%
Liechtenstein	0.11%
Finland	0.11%
Belgium	0.09%
Taiwan	0.08%
Denmark	0.08%
Portugal	0.05%
Netherlands	0.05%
Canada	0.05%
Austria	0.03%
South Africa	0.02%
Australia	0.02%
Singapore	0.02%
Japan	0.02%
Hong Kong	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

07-24 - Q2 2025 Earnings Release

More about the company